Abstract
Several studies have linked tumor-infiltration by regulatory T cells with poor patient outcome. Targeting the mechanisms by which regulatory T cells traffic to and persist in the tumor may circumvent tumor immune-escape by de-restricting T cell-mediated cytotoxicity. In this review, we describe the principle axes that govern regulatory T cell migration and the mechanisms that underpin their immunosuppressive activity in cancer. Inhibiting either the migration or function of regulatory T cells may enhance host-anti-cancer immune responses and as such are attractive and tractable targets for therapeutic intervention.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Cytokines / antagonists & inhibitors
-
Humans
-
Immunosuppression Therapy
-
Immunotherapy* / trends
-
Lymphocytes, Tumor-Infiltrating / drug effects
-
Lymphocytes, Tumor-Infiltrating / immunology
-
Lymphocytes, Tumor-Infiltrating / metabolism*
-
Neoplasms / drug therapy*
-
Neoplasms / immunology*
-
Neoplasms / pathology
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
T-Lymphocytes, Regulatory / drug effects
-
T-Lymphocytes, Regulatory / immunology
-
T-Lymphocytes, Regulatory / metabolism*
-
T-Lymphocytes, Regulatory / pathology
-
Tumor Escape
Substances
-
Antineoplastic Agents
-
Cytokines
-
Protein-Tyrosine Kinases